Nikhil Narang, MD

Status 1 heart transplant listings are increasing yearly, primarily driven by exceptions w/ exceptions being associated with a ⬇️ risk of delisting + ⬇️ rates of VA-ECMO Windfall from rise in Status 2 listings over time? Our work now in @JCardFail onlinejcf.com/article/S1071-…

Why are 100% of eligible patients with HFrEF w/o CI or intolerance not receiving quadruple GDMT? ARNI+BB+MRA+SGLT2i ➡️ 75% ⬇️ all-cause ☠️ (26% ARR, NNT=4, 24 months) 85% ⬇️ HF 🏨 (33% ARR, NNT=3, 24 months) Extend median survival by 7-11 years 💊 Cost $35/month

THIS is Chicago.

What #device therapies for advanced heart and lung failure are showing up in your clinic/research? Read the latest special edition of #JHLT, edited by Deputy Editor Manreet Kanwar and EIC Joseph Rogers, for reviews and research on #MCS, #ECMO, #LVADs, and #robotic devices.

🆕 Our meta-analysis is out in @JCardFail In-hospital initiation of #SGLT2i in acute #HeartFailure: ⬇️ All-cause mortality ⬇️ WHF events ⬇️ CV death @JamalRanaMD @robmentz @gcfmd #Cardiology #SGLT2inhibitors #CardioTwitter

🫀🔥 When myocarditis is not just myocarditis… A new study by sheds light on a critical and often under-recognised entity: desmosomal “hot-phase” cardiomyopathy (HPC). 💡 Why does this matter? Because HPC can mimic acute myocarditis, but carries a much higher arrhythmic risk and different clinical implications. 🔍 Key insights from the study: 👉 Patients with desmosomal HPC are often: • 👩‍⚕️ Young and female • 🧬 Carriers of desmosomal gene variants (mostly DSP) 👉 Compared to classic myocarditis, HPC shows distinctive “red flags”: 🧾 Clinical clues • Family history of cardiomyopathy / sudden cardiac death • Recurrent troponin elevations (“hot-phase” relapses) 🧲 Imaging clues (CMR) • Ring-like late gadolinium enhancement (LGE) • Right ventricular involvement • Persistent or progressive LGE • Incomplete recovery of LV function ⚡ Electrical clues • Low QRS voltages • High arrhythmic burden • Ventricular arrhythmias at a young age (<45 yrs) 📊 A practical takeaway A simple combination of: ➡️ Ring-like LGE ➡️ RV involvement ➡️ Family history 🎯 Achieved ~93% diagnostic accuracy in identifying HPC. 🚨 Clinical implication Recognising these red flags early can: ✔️ Prompt genetic testing ✔️ Improve risk stratification ✔️ Prevent life-threatening arrhythmias and adverse outcomes 💭 Bottom line: Not all myocarditis is inflammatory. Some cases are the first manifestation of a genetic cardiomyopathy. 👉 We need to think beyond the diagnosis and look for the phenotype. #Cardiology #Cardiomyopathy #Myocarditis #CMR #CardiacMRI #Arrhythmia #Genetics #PrecisionMedicine #DSP #ACM #HeartDisease #MedicalResearch #CardioTwitter doi.org/10.1161/JAHA.1…

@BarstoolChief Austin Matthews?

This review summarizes 💢 navigating diagnostic challenges of #HFpEF in setting of #AF 💢the #hemodynamics of HFpEF, with #heartrate & #rhythm implications 💢key drug & device #trials 💢drug classes that risk of AF in HFpEF 💢new RCTs @HeartOTXHeartMD heart.bmj.com/content/early/…

One of my favorite #SCAI2026 sessions was EAPCI/@SCAI Joint Session: ACS & #CardiogenicShock led by @EAPCIPresident Alaide Chieffo & @JDawnAbbott1. @thiele_holger w/fantastic opening lecture + great cases & commentary by @AlexandraLansky @HollandTamis @georgedangas Key slides 👇🏽

Presented at #HRS2026: In patients with persistent atrial fibrillation, first-line treatment with pulsed field ablation reduced the recurrence of atrial arrhythmias at 12 months as compared with antiarrhythmic drugs. Full AVANT GUARD trial results: nejm.org/doi/full/10.10… @HRSonline

Now in @JACCJournals led by HFC members @mvaduganathan, @scottdsolomon, @akshaydesaimd, et al A pooled analysis of TOPCAT, PARAGON-HF, DELIVER and FINEARTS-HF supports KCCQ-12 as an alternative to KCCQ-23 for assessing health status in HFmrEF/HFpEF trials doi.org/10.1016/j.jacc…

Educational and informative time @scai26! Thank you to my IC mentors for this project, @JKhambhati and Dr. Atman Shah, for the opportunity to present our centers experience on Navitor ViV interventions. Always grateful to @SandeepNathanMD for your mentorship and cheering me on! A great meeting to connect with old mentors and make new friends! Very grateful to the @UChicagoCardio cath lab team: @lroark10, Moira McDowell, and Janet Friant for taking care of these patients and supporting this work! @UChicagoMedPeds @UChicagoMed

This @radcliffeCARDIO Masterclass with Dr #EugeneBraunwald is poignant Achievement in the face of adversity, things he’d do differently if given a chance, & #lessons: A united family is everything It’s noble to work hard Be curious Choose the right mentor radcliffecardiology.com/Achievement-in…

Proud of our @healthallocate @UChiPritzker MS4 Stanton Greenstone at #ISHLT26 for his poster on applying US-CRS (continuous score to predict waitlist mortality) on listed patients with Amyloidosis and HCM US-CRS 📄 led by @WF_Parker in @JAMA_current jamanetwork.com/journals/jama/…

INTERMACS analysis on development of AI at 2 years in pts on microaxial flow pumps prior to HM3 LVAD therapy Important to safely bridge pts to MCS though downstream effects need close examination @JonGrinsteinMD @preventfailure Manreet Kanwar @UChicagoCardio #ISHLT26 @ISHLT

Expert LVAD APN @chickey22 presenting data on stellate ganglion block for refractory VT post LVAD implant who fail AAD -Similar 1 yr survival despite sicker SGB cohort -Safe and effective treatment option Congrats @chickey22 and @KanelidisMD #ishlt2026

Congrats rising ⭐️, @priyanair2024 on her @ISHLT poster. Initial Rx of PoPH and hemodynamic eligibility for liver tx 2️⃣ 💊 Trend to ⬆️ LT eligibility at 1 yr w/ dual Rx vs mono. 55.6% vs 18.2% p=0.08 🚫No intensification from mono tx at follow up = 0% LT eligibility #ishlt2026

HF with mildly reduced EF (HFmrEF) sits between HFrEF & HFpEF; where does it truly belong? A new HFSA Scientific Statement examines its epidemiology & pathophysiology & provides a comprehensive management framework for this understudied HF phenotype🫀 🔗 bit.ly/4sKAy21

With the changing landscape in #CAV management, this State of the Art Review on CAV explores how precision medicine may affect and change how we assess and manage CAV. @jukakimMD @NatalieTapaskar @KiranKhush1 @JoyceNjorogeMD 🔗: jhltonline.org/article/S1053-…

Excited to share the State-of-the-Art Review on Disease Prognosis and Progression in Transthyretin Amyloidosis @JACCJournals jacc.org/doi/10.1016/j.… @jvaishnavmd @maz_hanna @Ron_Witteles @dr_pavia @DBampatsias @MathewMaurer @rajshekharucms

As a pancreatic cancer doc, cannot understate the gravity of this moment. I get chills at the prospect that we will imminently have something else to offer our patients with real clinical impact. @AACR #AACR26 @RevMedicines